Work

Four-year landmark survival analysis of low-dose nivolumab added to metronomic chemotherapy in advanced head and neck squamous cell carcinoma: A phase III randomized trial.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.6054

Authors: Mehak Trikha, Vanita Noronha, Vijay Maruti Patil, Nandini Sharrel Menon, Minit Jalan Shah, Kavita Prakash Nawale, Riddhi Sawant, Kumar Prabhash

Institutions: Tata Memorial Hospital, Homi Bhabha National Institute, P. D. Hinduja Hospital and Medical Research Centre

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162563442

Cites:

Cited by: 1

Related to: